Magazine article Drug Topics

Pharmaceutical Outcomes Research on the Rise

Magazine article Drug Topics

Pharmaceutical Outcomes Research on the Rise

Article excerpt

Pharmacists who help make formulary decisions at managed care organizations are facing a rapidly increasing array of research reports from manufacturers arguing that their drug is best for patients, regardless of the price.

Drug companies are vastly expanding their drug therapy outcomes research efforts to be able to market their products better to managed care organizations, a recent survey found. The trend may indicate that price is not the only factor in decisions about which drugs get included on formularies.

From 1992 to 1993, many companies doubled the number of clinical outcomes research studies conducted for their products, according to recently released survey results from The Zitter Group, San Francisco.

On average, the number of outcomes research studies increased from seven to 10 per company, said the health-care information firm, which conducted the survey during February and March of this year. The results reflected responses from 29 of 53 pharmaceutical companies contacted.

Of the outcomes studies conducted this year, about 47% focus on economic analyses, 30% on quality-of-life issues, and 5% on utility analyses, the survey found. The rest dealt with a wide variety of other forms of outcomes analyses. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.